The Wall Street Journal’s Venture Capital Pro quoted a recent biopharma report from William Blair’s equity capital markets team, noting the uptick in activity for PIPEs among biopharma companies in 2023.
Investment Banking
Equity Capital Markets Team Quoted by The Wall Street Journal
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Clio Valued at $3B in $900M Series F Investment Led by NEA
William Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read moreWilliam Blair Raises Over $2.5B in Non-Control Financings in Q2 2024
Private capital markets have remained extremely active in recent years as company leaders and financial sponsors seek to utilize flexible, non-control capital solutions to generate partial liquidity, accelerate organic and inorganic growth, and optimize their balance sheets.
Read moreKKR Has Acquired a Majority Stake in Agiloft
William Blair served as exclusive financial advisor to KKR in connection with its acquisition of a majority stake in Agiloft, a portfolio company of FTV Capital (FTV).
Read more